Live Analyst Rating Changes 1525 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Gena Wang
BARC
Gena Wang
Wall Street Analyst
★★☆☆☆
#1898
on 13Foresight · ranked by our own returns
49%
Success Rate
+12.5%
Average Return
18 of 37 calls profitable · -1.1% vs benchmark
📈 Across the calls we could measure, roughly 49% of Gena Wang's ratings turned a profit when each position was held for 1 year — averaging +12.5% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

41 Buy 24 Hold 5 Sell
Gena's Stock Coverage 38 ratings · 2026-06-20
Company Date Position Consensus Price Target 1-Yr Return
CLLS
Cellectis SA
May 28, 2026 BUY Strong Buy
+573.5% avg upside
16 analysts
$9.00
202.07% Upside
·
CYTK
Cytokinetics
Dec 21, 2025 BUY Strong Buy
+8.9% avg upside
36 analysts
$87.00
10.38% Upside
+20.4%
RARE
Ultragenyx Pharmaceutical
Nov 24, 2025 BUY Strong Buy
+142.1% avg upside
36 analysts
$50.00
82.21% Upside
-29.5%
MRNA
Moderna
Nov 21, 2025 HOLD Hold
+6.1% avg upside
38 analysts
$25.00
60.84% Downside
+169.6%
KOD
Kodiak Sciences
Nov 17, 2025 HOLD Buy
+37.3% avg upside
11 analysts
$17.00
53.03% Downside
+80.1%
LEGN
Legend Biotech
Nov 13, 2025 BUY Strong Buy
+140.3% avg upside
27 analysts
$90.00
222.17% Upside
+15.7%
CRSP
Crispr Therapeutics AG
Nov 11, 2025 HOLD Buy
+39.1% avg upside
41 analysts
$56.00
3.59% Upside
-2.0%
VIR
Vir Biotechnology
Nov 11, 2025 BUY Strong Buy
+185.4% avg upside
16 analysts
$31.00
238.49% Upside
+62.9%
EDIT
Editas Medicine
Nov 11, 2025 HOLD Buy
+407.9% avg upside
33 analysts
$3.00
11.44% Upside
-0.6%
FDMT
4D Molecular Therapeutics
Nov 10, 2025 BUY Strong Buy
+265.2% avg upside
15 analysts
$33.00
241.58% Upside
-10.0%
VRTX
Vertex Pharmaceuticals
Nov 10, 2025 HOLD Strong Buy
-2.6% avg upside
61 analysts
$414.00
8.37% Downside
+9.0%
PBYI
Puma Biotechnology
Nov 07, 2025 SELL Buy
+458.2% avg upside
11 analysts
$2.00
73.51% Downside
-14.4%
NTLA
Intellia Therapeutics
Nov 07, 2025 BUY Buy
+151.9% avg upside
37 analysts
$14.00
10.57% Downside
+27.2%
ONC
BeOne Medicines
Nov 07, 2025 BUY Strong Buy
+28.4% avg upside
28 analysts
$385.00
42.61% Upside
-17.9%
RGNX
RegenXBio
Nov 07, 2025 BUY Strong Buy
+381.4% avg upside
22 analysts
$37.00
374.40% Upside
-49.0%
SGMO
Sangamo Therapeutics
Nov 07, 2025 HOLD Buy
+5844.2% avg upside
16 analysts
$1.00
473.06% Upside
-72.3%
SRPT
Sarepta Therapeutics
Nov 05, 2025 HOLD Buy
+244.5% avg upside
49 analysts
$20.00
14.15% Upside
-15.6%
PTCT
PTC Therapeutics
Nov 05, 2025 HOLD Buy
-1.5% avg upside
29 analysts
$68.00
13.80% Downside
+9.4%
BEAM
Beam Therapeutics
Nov 05, 2025 HOLD Strong Buy
+50.8% avg upside
25 analysts
$21.00
38.46% Downside
+27.4%
SLDB
Solid Biosciences
Nov 03, 2025 BUY Strong Buy
+90.3% avg upside
23 analysts
$9.00
8.03% Upside
+33.1%
BCRX
BioCryst
Nov 03, 2025 HOLD Strong Buy
+103.3% avg upside
24 analysts
$9.00
0.15% Upside
+22.9%
ALNY
Alnylam Pharma
Oct 31, 2025 BUY Strong Buy
+23.6% avg upside
51 analysts
$527.00
89.46% Upside
-38.0%
IONS
Ionis Pharmaceuticals
Oct 30, 2025 BUY Strong Buy
+13.3% avg upside
43 analysts
$95.00
28.18% Upside
-1.2%
BMRN
BioMarin Pharmaceutical
Oct 28, 2025 BUY Strong Buy
+72.8% avg upside
52 analysts
$80.00
46.31% Upside
+2.9%
RNA
Atrium Therapeutics, Inc.
Aug 07, 2025 BUY Strong Buy
+171.3% avg upside
4 analysts
$62.00
389.82% Upside
-14.2%
TECX
Tectonic Therapeutic
Aug 10, 2023 BUY Strong Buy
+88.0% avg upside
24 analysts
$48.00
59.97% Upside
-13.8%
ZYME
Zymeworks
Dec 22, 2022 HOLD Strong Buy
+40.3% avg upside
25 analysts
$9.00
61.18% Downside
+11.8%
ARCT
Arcturus Therapeutics
Nov 02, 2022 HOLD Buy
+290.9% avg upside
35 analysts
$25.00
232.02% Upside
-14.2%
MGTX
Meiragtx Holdings
May 13, 2022 BUY Strong Buy
+130.4% avg upside
13 analysts
$18.00
59.04% Upside
-33.8%
DTIL
Precision BioSciences
Mar 15, 2022 BUY Strong Buy
+247.1% avg upside
12 analysts
$6.00
11.98% Downside
-69.6%
TVTX
Travere Therapeutics
Jul 30, 2020 HOLD Strong Buy
-16.0% avg upside
22 analysts
$21.00
61.96% Downside
-33.5%
HALO
Halozyme
May 12, 2020 HOLD Strong Buy
-13.7% avg upside
20 analysts
$21.00
69.27% Downside
+79.6%
ATRA
Atara Biotherapeutics
Jun 22, 2017 BUY Buy
+79.6% avg upside
18 analysts
$30.00
197.85% Upside
+186.4%
ABEO
Abeona Therapeutics
Jan 20, 2017 BUY Strong Buy
+195.8% avg upside
17 analysts
+192.0%
REGN
Regeneron
Aug 17, 2016 HOLD Strong Buy
+26.9% avg upside
57 analysts
+12.7%
QURE
uniQure
Jul 22, 2016 BUY Strong Buy
+16.1% avg upside
29 analysts
+14.2%
PFE
Pfizer
Jul 22, 2016 BUY Buy
+34.2% avg upside
45 analysts
-5.3%
TPST
Tempest Therapeutics
Mar 17, 2015 BUY Buy
+1669.9% avg upside
18 analysts
$56.00
4452.89% Upside
-81.2%
🔒 33 more ratings — with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
Gena Wang — Frequently Asked Questions
How accurate are Gena Wang's stock ratings?
Based on the calls 13Foresight could measure, about 49% of Gena's ratings were profitable over a one-year hold, with an average return of +12.5% per rating, or -1.1% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Gena ranked on 13Foresight?
Gena Wang is currently ranked #1898 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Gena cover?
Gena most recently has ratings on CLLS, CYTK, RARE, MRNA, KOD, LEGN, CRSP, VIR, EDIT, FDMT, VRTX, PBYI and 26 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.